Table 1. Distribution of NOD2, ATG16L1, IRGM, CARD9 and ORMDL3 risk alleles and clinical characteristics in ileal CD, colitis and non-IBD subjects in batches 1 and 2.
The percent of subjects recruited at each of the three IBD centers with complete genotype and clinical characteristics with at least one risk allele and the percent of subjects who have at least one risk allele (see Methods) are listed.
| Ileal CD | Colitis | Non-IBD | |||||||
|---|---|---|---|---|---|---|---|---|---|
| n = 106 | n = 88 | n = 89 | |||||||
| Batch1 | Batch2 | P value | Batch1 | Batch2 | P value | Batch1 | Batch2 | P value | |
| n = 50 | n = 56 | n = 59 | n = 29 | n = 56 | n = 33 | ||||
| IBD Center | |||||||||
| Wash. U.-St. Louis | 100% | 62% | 100% | 83% | 100% | 73% | |||
| Stony Brook U. | 0% | 9% | 0% | 17% | 0% | 27% | |||
| U. of North Carolina | 0% | 29% | 0% | 0% | 0% | 0% | |||
| IBD Risk Allele | |||||||||
| NOD2R composite | 40% | 30% | 0.38 | 19% | 14% | 0.78 | 14% | 52% | <0.001 |
| ATG16L1R | 94% | 79% | 0.05 | 81% | 76% | 0.79 | 77% | 79% | 0.99 |
| IRGMR | 30% | 27% | 0.90 | 29% | 17% | 0.34 | 27% | 18% | 0.38 |
| CARD9R | 94% | 96% | 0.98 | 93% | 93% | 1 | 88% | 91% | 0.85 |
| XBP1R | 12% | 14% | 0.99 | 10% | 14% | 0.84 | 14% | 0% | 0.01 |
| ORMDL3R | 76% | 73% | 0.90 | 75% | 79% | 0.88 | 62% | 70% | 0.51 |
| Clinical covariates | |||||||||
| Male gender % | 46% | 43% | 0.91 | 53% | 55% | 1 | 41% | 39% | 0.99 |
| Caucasian race % | 94% | 82% | 0.11 | 91% | 97% | 0.55 | 89% | 94% | 0.56 |
| Median age years (range) |
33 (18–72) |
32 (17–67) |
44 (18–69) |
47 (20–72) |
61 (24–84) |
62 (17–86) |
|||
| Duration IBD years (range) |
5 (0–38) |
5 (0–35) |
5 (0–45) |
5 (0.1–30) |
NA | NA | |||
| Current smoker % | 32% | 29% | 0.90 | 10% | 3% | 0.46 | 27% | 18% | 0.38 |
| + fecal C. difficile toxin % | 0% | 5% | 0.32 | 24% | 0% | 0.01 | 0% | 6% | 0.23 |
| Colon Cancer % | 6% | 0% | 0.20 | 17% | 3% | 0.13 | 54% | 45% | 0.46 |
| Median BMI kg/m2 (range) |
24 (16–41) |
23 (14–44) |
26 (16–43) |
28 (19–36) |
28 (18–47) |
26 (20–48) |
|||
| 5-ASA % | 60% | 38% | 0.04 | 63% | 48% | 0.27 | 0% | 3% | 0.65 |
| Steroids % | 48% | 54% | 0.67 | 54% | 52% | 1 | 2% | 12% | 0.11 |
| Immunomodulators % | 48% | 30% | 0.09 | 29% | 28% | 1 | 4% | 6% | 0.98 |
| Anti-TNF alpha % | 24% | 45% | 0.04 | 31% | 52% | 0.09 | 2% | 0% | 0.96 |